NDAINHALATIONAEROSOL, METERED
Approved
Jun 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DULERA is a combination inhaled corticosteroid (mometasone furoate) and long-acting beta-2 agonist (formoterol fumarate dihydrate) approved by the FDA on June 22, 2010, for maintenance treatment of asthma. It is delivered via metered-dose aerosol inhaler for twice-daily dosing. The combination provides both anti-inflammatory and bronchodilator effects to reduce airway obstruction and asthma symptoms. DULERA is positioned as a maintenance therapy option for moderate-to-persistent asthma patients requiring combination ICS/LABA therapy.
$0.1BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence
Started Mar 2014
50 enrolled
Asthma
Why This Matters for Your Career
$117M Medicare spend — this is a commercially significant brand
Worked on DULERA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.